Close
ImmunoCard
Immunocard® Toxins A&B

A rapid, sensitive enzyme immunoassay for the detection of Clostridium difficile toxins A and B in stool specimens.

Catalog Number: 712050

Support & Documents

Definitive answers, confidence in results

Contact Sales

Definitive answers, confidence in results

Contact Sales

Support & Documents

Downloadable PDFs

FAQs

Colonization is more common than C. diff infection. The patient exhibits NO clinical symptoms (asymptomatic) but may test positive for the C.diff organism or its toxin gene. With infection, the patient exhibits clinical symptoms and tests positive for the C.diff organism and/or its toxin.

Use a stool toxin test as part of a multistep algorithm (ie, glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin, arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) rather than a NAAT alone for all specimens received in the clinical laboratory when there are no pre-agreed institutional criteria for patient stool submission.

Use a NAAT alone or a multistep algorithm for testing (ie, GDH plus toxin; GDH plus toxin, arbitrated by NAAT; or NAAT plus toxin) rather than a toxin test alone when there are pre-agreed institutional criteria for patient stool submission.

Can such a subset predict a more ill cohort? There are insufficient data to recommend use of biologic markers as an adjunct to diagnosis.

The 2018 MDRO/CDI Protocol states that the results of the final test that are placed in the patient’s medical record should be used to determine whether or not the even meets the CDI LabID Event definition. That means that facilities using a multi-step testing algorithm for C. difficile will be entering LabID events in NHSN based on the results of the final test in the algorithm.

In 2017, the CDI testing algorithm of “NAAT plus EIA, if NAAT-positive” received the “NAAT” level of risk adjustment.  Now the CDI testing algorithm of “NAAT plus EIA, if NAAt-positive” is assigned the “EIA” level of risk adjustment. Facilities using this algorithm should only enter CDI LabID events into NHSN if the results from the EIA test are positive.

Immunocard® Toxins A&B – 87324

Para-Pak

The Para-Pak system provides a standardized procedure for the routine collection, transport, preservation, and culture of stool specimens for bacterial enteric pathogens. Learn More.

Learn More

“With Meridian’s molecular C. difficile test as the primary method, we’re getting results faster, with higher throughput.” Classifying these patients as noninfectious resulted in a cost-savings of approximately $100,000 to the facility, all while only increasing the lab’s spend on testing by $3,000 with the implementation of the ImmunoCard® Toxins A&B.

Southern Ohio

Get in touch with us

Contact Us

Welcome to

Please select your country to continue

Continue